Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in September 2014 on request of the sponsor.
On 9 August 2012 orphan designation (EU/3/12/1032) was granted by the European Commission to Novo Nordisk A/S, Denmark, for vatreptacog alfa (activated) for the treatment of haemophilia B.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Vatreptacog alfa (activated)
Treatment of haemophilia B
|Date of designation||
|Orphan designation status||
|EU designation number||
Review of designation
Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in September 2014 on request of the sponsor, before marketing authorisation had been granted.
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.